At a glance
ClinicalIndex Comparison RecordN/ACompleted· 765 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension
In Brief
A clinical study evaluating Placebo and DS-5565 for Post-Herpetic Neuralgia. Completed, enrolled 765 participants across 1 site.
Detailed Summary
Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Herpetic Neuralgia
CountriesJapan
CollaboratorsSRL Medisearch Inc., Quintiles, Inc.
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedDec 17, 2014
Enrollment StartJan 1, 2015
Primary CompletionMay 25, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.5 years ago
Interventions
Placebodrug
Placebo
DS-5565drug